Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of 9MW2821 plus toripalimab in the perioperative treatment of urothelial carcinoma
CTR20252267Phase 2Active
- Sponsor
- Mabwell
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bulumtatug fuvedotin and toripalimab in transitional cell carcinoma (TCC), sponsored by Mabwell. Started Aug 2025; status: active.
02
Drugs
bulumtatug fuvedotintoripalimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20252267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252267.